Meeting
2017 ASCO Annual Meeting
The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.
Authors
Wilson I. Gonsalves
Division of Hematology, Mayo Clinic, Rochester, MN
Wilson I. Gonsalves , S. Vincent Rajkumar , Angela Dispenzieri , Martha Lacy , Francis Buadi , David Dingli , Ronald S. Go , Prashant Kapoor , Suzanne R. Hayman , John Anthony Lust , Nelson Leung , Stephen J. Russell , Steven R. Zeldenrust , Yi Lin , Yi Lisa Hwa , Taxiarchis Kourelis , Robert A. Kyle , Morie A. Gertz , Shaji Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8032)
DOI
10.1200/JCO.2017.35.15_suppl.8032
Abstract #
8032
Poster Bd #
358
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.
First Author: Theresia Akhlaghi
Poster
2014 ASCO Annual Meeting
Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).
First Author: Rashid Khan
Poster
2024 ASCO Annual Meeting
From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
First Author: Mengmeng Ji
Poster
2023 ASCO Annual Meeting
Association between excess body mass index trajectory and change in monoclonal protein level in patients diagnosed with monoclonal gammopathy of undetermined significance.
First Author: Lawrence Liu